任意の製品分析
許可いただいた場合、プライバシーに配慮した限定的な分析を使用し、どのリサーチ経路が有効かを把握します。広告トラッカーやセッション録画は使用しません。この選択は設定で変更できます。詳しくは プライバシーポリシー.
Church & Dwight Co., Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $23.2B | |
|---|---|---|
| Revenue (ttm) | 6.2B | |
| Net income (ttm) | 744.8M | |
| EPS (ttm) | $3.11 | |
| Shares out | 237.2M | |
| P/E (trailing) | 33.6x | |
| P/E (forward) | 23.4x | |
| Dividend | $1.23 (1.17%) | |
| Volume | 1,114,784 | |
| Beta | 0.48 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.19B | $5.38B | $5.87B | $6.11B | $6.20B | +4.6% |
| Gross profit | $2.26B | $2.25B | $2.59B | $2.79B | $2.77B | +5.2% |
| Operating income | $1.08B | $597.8M | $1.06B | $807.1M | $1.08B | -0.0% |
| Net income | $827.5M | $413.9M | $755.6M | $585.3M | $736.8M | -2.9% |
| EPS (diluted) | $3.32 | $1.68 | $3.05 | $2.37 | $3.02 | -2.3% |
| EBITDA | $1.31B | $831.9M | $1.06B | $1.09B | $1.30B | -0.1% |
| R&D | $105.2M | $110.0M | $122.4M | $139.7M | $145.6M | +8.5% |
| SG&A | $606.7M | $706.0M | $889.8M | $927.8M | $988.3M | +13.0% |
Recent company headlines from major financial publishers.
The Base scenario reflects the modal operating trajectory. Consumer Domestic anchors consolidated revenue with steady volume compounding in specialty personal care offsetting flattish volume trends in mature laundry categories. Management achieves guided gross margin expansion through continuous productivity and trade optimization, while holding brand marketing at guided levels relative to sales to defend shelf space against scale peer affordability campaigns. Cash flow conversion remains robust, supporting modest annual dividend increases and disciplined bolt-on acquisitions.
Under the Bull scenario, international consumer distribution expands rapidly across Europe and Latin America, while domestic market share gains in TheraBreath and Hero accelerate as household penetration closes the gap toward broader category averages. Manufacturing productivity programs and trade optimization deliver gross margin expansion surpassing guidance, lifting operating margins beyond historical averages and driving superior free cash flow compounding.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 6.7% | $88.1 | $91.2 | $94.6 | $98.5 | $103 |
| 7.2% | $81.6 | $84.0 | $86.7 | $89.7 | $93.1 |
| 7.7% | $76.2 | $78.2 | $80.3 | $82.7 | $85.3 |
| 8.2% | $71.7 | $73.3 | $75.0 | $76.9 | $79.1 |
| 8.7% | $67.8 | $69.1 | $70.6 | $72.2 | $73.9 |
Upcoming earnings date and setup when available.
各月に公開されたリサーチ版が示したレーティングです。レーティングは分析時点の株価を公正価値と比較したもので、判断が当たったかどうかの記録ではありません。
| 年 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |